Biofilm Formation and Increased Mortality Among Cancer Patients with Candidemia in a Peruvian Reference Center

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Oct 12

PMID 39395965

Authors

Freddy Villanueva-Cotrina

Vilma Bejar

Jose Guevara

Ines Cajamarca

Cyntia Medina

Luis Mujica

Andres G Lescano

Affiliations

Soon will be listed here.

Abstract

Background: Candidemia is an invasive mycosis with an increasing global incidence and high mortality rates in cancer patients. The production of biofilms by some strains of Candida constitutes a mechanism that limits the action of antifungal agents; however, there is limited and conflicting evidence about its role in the risk of death. This study aimed to determine whether biofilm formation is associated with mortality in cancer patients with candidemia.

Methods: This retrospective cohort study included patients treated at Peru's oncologic reference center between June 2015 and October 2017. Data were collected by monitoring patients for 30 days from the diagnosis of candidemia until the date of death or hospital discharge. Statistical analyses evaluated the association between biofilm production determined by XTT reduction and mortality, adjusting for demographic, clinical, and microbiological factors assessed by the hospital routinary activities. Survival analysis and bivariate and multivariate Cox regression were used, estimating the hazard ratio (HR) as a measure of association with a significance level of p < 0.05.

Results: A total of 140 patients with candidemia were included in the study. The high mortality observed on the first day of post-diagnosis follow-up (81.0%) among 21 patients who were not treated with either antifungal or antimicrobial drugs led to stratification of the analyses according to whether they received treatment. In untreated patients, there was a mortality gradient in patients infected with non-biofilm-forming strains vs. low/medium and high-level biofilm-forming strains (25.0%, 66.7% and 82.3%, respectively, p = 0.049). In treated patients, a high level of biofilm formation was associated with increased mortality (HR, 3.92; 95% p = 0.022), and this association persisted after adjusting for age, comorbidities, and hospital emergency admission (HR, 6.59; CI: 1.87-23.24, p = 0.003).

Conclusions: The association between candidemia with in vitro biofilm formation and an increased risk of death consistently observed both in patients with and without treatment, provides another level of evidence for a possible causal association. The presence of comorbidities and the origin of the hospital emergency, which reflect the fragile clinical condition of the patients, and increasing age above 15 years were associated with a higher risk of death.

References

Huang L, Wang W, Chen T, Yen C, Yang M, Hsiao L . Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. J Infect. 2009; 58(2):154-60. DOI: 10.1016/j.jinf.2008.12.008. View

Bergamasco M, Garnica M, Colombo A, Nucci M . Epidemiology of candidemia in patients with hematologic malignancies and solid tumours in Brazil. Mycoses. 2012; 56(3):256-63. DOI: 10.1111/myc.12013. View

Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M . Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014; 40(9):1303-12. PMC: 4147247. DOI: 10.1007/s00134-014-3408-3. View

Wisplinghoff H, Bischoff T, Tallent S, Seifert H, Wenzel R, Edmond M . Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39(3):309-17. DOI: 10.1086/421946. View

Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de Pipaon M, Hernandez-Caballero C, Lepe-Jimenez J . Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother. 2012; 68(1):206-13. DOI: 10.1093/jac/dks347. View

Asmundsdottir L, Erlendsdottir H, Gottfredsson M . Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol. 2002; 40(9):3489-92. PMC: 130691. DOI: 10.1128/JCM.40.9.3489-3492.2002. View

Stergiopoulou T, Meletiadis J, Sein T, Papaioannidou P, Tsiouris I, Roilides E . Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother. 2008; 63(2):343-8. PMC: 2734084. DOI: 10.1093/jac/dkn473. View

Tascini C, Sozio E, Corte L, Sbrana F, Scarparo C, Ripoli A . The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data. Infect Dis (Lond). 2017; 50(3):214-219. DOI: 10.1080/23744235.2017.1384956. View

Gurlek Gokcebay D, Yarali N, Isik P, Bayram C, Ozkaya-Parlakay A, Kara A . Candida Associated Bloodstream Infections in Pediatric Hematology Patients: A Single Center Experience. Mediterr J Hematol Infect Dis. 2016; 8(1):e2016018. PMC: 4771141. DOI: 10.4084/MJHID.2016.018. View

10.

Tumbarello M, Posteraro B, Trecarichi E, Fiori B, Rossi M, Porta R . Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol. 2007; 45(6):1843-50. PMC: 1933062. DOI: 10.1128/JCM.00131-07. View

11.

Velasco E, Bigni R . A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis. 2008; 27(11):1071-8. DOI: 10.1007/s10096-008-0546-y. View

12.

Rajendran R, Sherry L, Nile C, Sherriff A, Johnson E, Hanson M . Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection-Scotland, 2012-2013. Clin Microbiol Infect. 2015; 22(1):87-93. PMC: 4721535. DOI: 10.1016/j.cmi.2015.09.018. View

13.

Hawser S, Norris H, Jessup C, Ghannoum M . Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-t etrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast.... J Clin Microbiol. 1998; 36(5):1450-2. PMC: 104852. DOI: 10.1128/JCM.36.5.1450-1452.1998. View

14.

Sievert D, Ricks P, Edwards J, Schneider A, Patel J, Srinivasan A . Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2012; 34(1):1-14. DOI: 10.1086/668770. View

15.

Basu S, Gugnani H, Joshi S, Gupta N . Distribution of Candida species in different clinical sources in Delhi, India, and proteinase and phospholipase activity of Candida albicans isolates. Rev Iberoam Micol. 2004; 20(4):137-40. View

16.

Kumamoto C . Candida biofilms. Curr Opin Microbiol. 2002; 5(6):608-11. DOI: 10.1016/s1369-5274(02)00371-5. View

17.

Ruzicka F, Hola V, Votava M, Tejkalova R . [Detection and significance of biofilm formation in yeasts isolated from hemocultures]. Klin Mikrobiol Infekc Lek. 2006; 12(4):150-5. View

18.

Pappas P . Invasive candidiasis. Infect Dis Clin North Am. 2006; 20(3):485-506. DOI: 10.1016/j.idc.2006.07.004. View

19.

Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, Cecilia T . A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014; 40(6):839-45. DOI: 10.1007/s00134-014-3310-z. View

20.

Ma C, Li F, Shi L, Hu Y, Wang Y, Huang M . Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China. BMC Infect Dis. 2013; 13:337. PMC: 3723814. DOI: 10.1186/1471-2334-13-337. View